|
Back to List
|
Title:
Author:
Date:
Source:
|
Patient Response to Triptans vs. Other
Anti-migraine Drugs
in Different Migraine Types:
A Clinical Practice Study
Kelman L.
Posted August 2003
Presented at: 45th Annual Scientific Meeting
American Headache Society
June 19-22, 2003; Chicago, Illinois
|
Objectives: In this study patients response to triptan versus
non-triptan therapy was assessed in a clinical practice setting. In addition,
this study attempted to draw a relationship between patient response (efficacy or
adverse response) to triptan treatment and patient variability in terms of headache
characteristics, social, psychological, and personal characteristics disability,
sleep patterns, and women’s issues.
Conclusions: In this study, patients rated a better treatment response
to triptans than non-triptans and anti-inflammatories in the symptomatic treatment
of migraine. Although variations in triptan response were found between headache
type and triptan medication at the initial visit, these were nullified when
treatment was tailored to individual headache characteristics. Ideally if the
right triptan can be found for each patient then a better triptan response can be
achieved across all headache types. Patients chose triptans based more on efficacy
than side effects. Most perceived adverse effects are due to the medication and
not the headache. Each triptan efficacy and adverse effects rating in practice
tends to gravitate to the mean due to bias in prescribing triptans and other
treatments. Triptans are more effective than non-triptans across a wide range of
migrainous disorders but not in transformed migraine. Specifically triptans are
effective in IHS 1.7 migraine. Triptan efficacy is no different in teens from other
age groups. Triptan responsiveness is correlated with decreased headache frequency,
with aura with visual symptoms, not eating and perfume triggers, decreased number of
children, and less excess sleep.
|
